Try our Advanced Search for more refined results
Health
-
March 23, 2026
Emory Healthcare Defeats Black Nurse's Retaliation Suit
Emory Healthcare has escaped a suit brought by a Black travel nurse alleging she was fired for complaining about receiving less training than white nurses, a Georgia federal judge ruled Monday, finding the nurse failed to show she engaged in protected activity.
-
March 23, 2026
Stem Cell Clinic Accused Of Deceiving Patients
An operator of clinics offering stem cell and plasma therapies lures in desperate patients for unproven treatments marketed as guaranteed cures with no-interest payments, according to a proposed class suit filed Monday in Miami.
-
March 23, 2026
Nursing Home Atty Fees Axed Over Lack Of Proximate Cause
A New Jersey appellate panel has ruled that an estate can't recover attorney fees under the state statute governing nursing home residents' rights because the jury in an underlying wrongful‑death and negligence trial found no damages tied to any statutory violation.
-
March 23, 2026
FTC Stays Focused On Healthcare, Launches Task Force
The Federal Trade Commission announced it is launching a new task force with staff from across the agency to coordinate healthcare policy approaches and initiate investigations meant to help protect patients, healthcare workers and American taxpayers.
-
March 23, 2026
Novartis Faces Class Suit Over Patient Health Info Disclosure
Drugmaker Novartis collected patients' personal and health information through pharmaceutical marketing websites and transmitted it to third parties including Google using "surreptitious online tracking tools" without patients' consent, a proposed class action in New Jersey federal court alleges.
-
March 23, 2026
Md. Judge Rules Written Consent Not Needed Under TCPA
Echoing a recent Fifth Circuit ruling, a Maryland federal judge has held that written consent to receive telemarketing calls is not required under the Telephone Consumer Protection Act, reversing a decision to certify a class of consumers against a dental plan marketer.
-
March 23, 2026
Pediatric Data Breach Class Action Can Stay In NC Biz Court
A consolidated class action alleging a pediatric medical practice failed to protect minor patients' data from hackers can remain in the North Carolina Business Court, a judge ruled in finding the lawsuits were properly designated to the state's specialized superior court for complex business matters.
-
March 23, 2026
Injury Law Roundup: Meta Atty Uses Jane Doe Plaintiff's Name
A Meta attorney's gaffe and Mark Zuckerberg's testimony in the closely watched social media addiction bellwether trial, and an announced $7.25 billion settlement by Bayer over Roundup weedkiller claims, lead Law360's Injury Law Roundup.
-
March 23, 2026
Progressive Escapes Workers' Tobacco, Vaccine Fee Suit
Allegations that Progressive Corp. wrongly charged higher health premiums from workers who used tobacco or refused the COVID-19 vaccination failed to state a claim for violating federal benefits law, an Ohio federal judge ruled as he tossed a proposed class action against the insurance giant.
-
March 23, 2026
Duke Health's $3.7M Pixel Privacy Deal Gets Initial OK
Hundreds of thousands of Duke University Health System Inc. patients are one step closer to securing a share of a $3.7 million settlement stemming from a health data tracking suit involving Meta's Pixel, after a North Carolina federal court granted preliminary approval of the class action settlement.
-
March 23, 2026
Healthcare Co. Liable For Patient's Killings, Philly Jury Told
A healthcare management company's failure to submit proper paperwork prohibiting a man who was committed to a hospital for psychosis allegedly enabled him to buy the shotgun he used to slay his family, counsel for their estates told a Philadelphia jury Monday.
-
March 23, 2026
Feds Approve Minnesota's Plan To Combat Medicaid Fraud
Minnesota may soon receive the release of $243 million in deferred Medicaid funds after the Centers for Medicare & Medicaid Services approved the state's updated plan to combat Medicaid fraud, Minnesota state health officials told a federal court last week.
-
March 23, 2026
Health Insurers Can't Force Conn. ERISA Row Into Arbitration
Elevance Inc. can't compel arbitration of a union health plan's allegations the insurer caused it to pay excessive administrative fees and medical costs, a Connecticut federal judge ruled, finding the insurer and its subsidiaries waived that right by seeking to dismiss the proposed class action.
-
March 23, 2026
AbbVie Escapes Ill. Genetic Privacy Lawsuit
An Illinois federal judge on Friday granted AbbVie summary judgment in a lawsuit claiming it violated the state's genetic privacy law, saying there was "no genuine dispute" that AbbVie never conditioned the plaintiff's employment on whether he disclosed genetic information in the physical exam he was required to undergo before starting work.
-
March 23, 2026
High Court Won't Hear Mich. Newborn Blood Testing Case
The U.S. Supreme Court on Monday declined to hear a petition from parents seeking to revive claims that the way newborn blood samples are collected and stored in a Michigan health screening program violates their rights to make medical decisions for their children.
-
March 23, 2026
Sidley, Kirkland Steer $1.1B Sale Of EyeSouth's Retina Biz
Private equity shop Olympus Partners, advised by Kirkland & Ellis LLP, on Monday unveiled plans to sell the retina business of EyeSouth Partners to Sidley Austin LLP-led Cencora Inc. in a $1.1 billion deal.
-
March 23, 2026
Trinity, Health Gorilla Sued Over Patient Data Breach
Trinity Health Corp. and Health Gorilla Inc. were hit with a proposed class action in Michigan federal court alleging that they failed to protect the sensitive personal information of patients whose data was improperly disclosed through a health information exchange platform.
-
March 23, 2026
Justices Won't Review Lab Owner's Kickback Conviction
The U.S. Supreme Court on Monday declined to review the conviction of a former California biotech president sentenced to eight years in prison for lying about the efficacy of his company's COVID-19 and allergy testing and conducting a $70 million Medicare fraud scheme.
-
March 23, 2026
High Court Won't Hear Calif. Border Hospital Medicaid Fight
The U.S. Supreme Court said Monday it would not consider a case challenging California's exclusions of hospitals in neighboring states from supplemental federal payments going to providers that serve Medi-Cal beneficiaries.
-
March 23, 2026
Justices Pass On Challenge To Courts' Sanctions Authority
The U.S. Supreme Court on Monday declined a dietary supplement company's request to review sanctions it was issued at trial in a false advertising dispute, in a case that could have led justices to clarify when courts may use their inherent authority to sanction parties for litigation conduct.
-
March 20, 2026
Feds Rip Ex-NFL Player's New Trial Bid Over Medicare Scheme
The federal government opposed a new trial bid by Keith Gray, a former NFL player and Texas laboratory owner convicted in a $328 million scheme involving billing for unnecessary cardiovascular genetic testing for Medicare beneficiaries, arguing Thursday he lacks any valid basis to "disturb the jury's sound verdict."
-
March 20, 2026
Former Gilead Sciences GC To Earn Over $2.5M Severance
Gilead Sciences Inc. is paying its former general counsel more than $2.5 million in severance after she left the company, according to a U.S. Securities and Exchange Commission filing released Friday.
-
March 20, 2026
CytoDyn Settles Investor Suit With $500K, 49M Shares
Biotechnology firm CytoDyn has agreed to dole out 49 million shares of common stock and pay $500,000 to end investors' proposed class action accusing the company of overstating the likelihood that the U.S. Food and Drug Administration would approve a drug it claimed could treat HIV and COVID-19.
-
March 20, 2026
EPA's Ethylene Oxide Plan May Hinder Other Air Toxics Regs
A new proposal from the U.S. Environmental Protection Agency to weaken emission standards for a medical sterilizer could have broader implications for the agency's power to tighten air pollution limits when new science becomes available.
-
March 20, 2026
Expert's Conflicting Testimony Dooms Med Mal Case In NJ
A New Jersey appellate panel on Friday tossed a suit accusing an emergency room physician of negligently prescribing a drug to a patient that allegedly caused his cognitive decline, saying the plaintiff's sole medical expert's improper deposition testimony was fairly excluded by the trial court.
Expert Analysis
-
Series
Judges On AI: How Judicial Use Informs Guardrails
U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.
-
Lessons From EdTech Provider's Data Breach Settlements
Education technology company Illuminate Education's recent settlements with three states and the Federal Trade Commission over state privacy law claims following a student data breach are some of the first of their kind, suggesting a shift in enforcement focus to how companies handle student data and highlighting the potential for coordinated enforcement actions, say attorneys at Wilson Sonsini.
-
Justices' Med Mal Ruling May Spur Huge Shift For Litigators
The U.S. Supreme Court’s recent decision in the medical malpractice suit Berk v. Choy, holding that a Florida procedural requirement does not apply to medical malpractice claims filed in federal court, is likely to encourage eligible parties to file claims in federal court, speed the adjudicatory process and create both opportunities and challenges for litigators, says Thomas Kroeger at Colson Hicks.
-
What US Cos. Must Know To Comply With Italy's AI Law
Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.
-
Key Sectors, Antitrust Risks In Pricing Algorithm Litigation
Algorithmic pricing lawsuits have proliferated in rental housing, hotels, health insurance and equipment rental industries, and companies should consider emerging risk factors when implementing business strategies this year, say attorneys at Hunton.
-
Ag Bill Wording Presents Existential Threat To Hemp Industry
A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.
-
Series
Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief
My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.
-
5 Drug Pricing Policy Developments To Watch In 2026
2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.
-
Prisoners' Access To Health Info Should Have No Bars
To safeguard against unnecessary deaths in custody, courts and policymakers should clarify that incarcerated individuals’ constitutional right to medical care also includes access to sufficient information about their medical conditions, lifting current restrictions that can lead to crucial information being withheld, says Jaehyun Oh at Jacob Fuchsberg Law.
-
Navigating The New Wave Of Voluntary Benefit ERISA Suits
Four recent complaints claiming that employees pay unreasonable premiums for voluntary benefit programs contribute to a trend in Employee Retirement Income Security Act class actions targeting employers and benefits consultants over such programs, increasing scrutiny of how the programs are selected, priced and administered, say attorneys at Holland & Knight.
-
Series
Law School's Missed Lessons: How To Start A Law Firm
Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.
-
Justices' Med Mal Ruling May Hurt Federal Anti-SLAPP Suits
The U.S. Supreme Court's recent decision in Berk v. Choy restricts the application of certain state laws in diversity actions in federal court — and while the ruling concerned affidavit requirements in medical malpractice suits, it may also affect the use of anti-SLAPP statutes in federal litigation, says Travis Chance at Brownstein Hyatt.
-
Regulatory Uncertainty Ahead For Organ Transplant System
Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.
-
Key False Claims Act Trends From The Last Year
The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.
-
Opinion
It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs
The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.